---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-168911"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2022-06-07T23:59:59+00:00"
generated_at: "2026-06-25T03:52:40.390531+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Forte Biosciences appoints Dr. Hubert Chen as President and CSO

## Summary
- Dr. Chen appointed President and Chief Scientific Officer effective June 7, 2022; Paul Wagner remains CEO.
- Annual base salary of $450,000, target annual bonus of 40% of base salary, and option for 250,000 shares.
- Dr. Chen previously served as CMO of Metacrine and CSO/CMO of Pfenex, leading PF708 NDA and MAA approvals.
- Options vest 25% after one year, remaining monthly over 36 months; grant under 2020 Inducement Equity Incentive Plan.

## SEC filing metadata
- accession: 0001193125-22-168911
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2022-06-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312522168911/0001193125-22-168911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312522168911/d274694d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-168911
- JSON: https://secwatch.observer/filing/0001193125-22-168911.json
- Plain text: https://secwatch.observer/filing/0001193125-22-168911.txt

## Key facts
- Executive change
  Paul A. Wagner changed role as President at Forte Biosciences, Inc..
  - Action: transitioned
  - Role: President
  source text: the title of President of the Company transitioned from Paul A. Wagner, Ph.D. to Dr. Chen, provided that Dr. Wagner will continue to serve as the Company’s Chief Executive Officer and a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312522168911/0001193125-22-168911-index.htm
- Executive change
  Hubert C. Chen was appointed as President and Chief Scientific Officer at Forte Biosciences, Inc..
  - Action: appointed
  - Role: President and Chief Scientific Officer
  source text: On June 5, 2022, the Board of Directors (“Board”) of Forte Biosciences, Inc. (the “Company”) appointed Hubert C. Chen, M.D. to serve as President and Chief Scientific Officer of the Company, effective June 7, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312522168911/0001193125-22-168911-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.